Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 4/20 | 0.47 |
| ▸ | BCL9 | O00512 | 5/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23752826 | 0.90 | NOTUM (0.49) | NOTUMMGLLBCL9CTNNB1HSD11B1 | |
| SCHEMBL30177218 | 0.90 | NOTUM (0.49) | NOTUMMGLLBCL9CTNNB1HSD11B1 | |
| SCHEMBL23752824 | 0.90 | NOTUM (0.49) | NOTUMMGLLBCL9CTNNB1HSD11B1 | |
| SCHEMBL23752827 | 0.90 | NOTUM (0.49) | NOTUMMGLLBCL9CTNNB1HSD11B1 | |
| SCHEMBL21381632 | 0.90 | NOTUM (0.52) | NOTUMMGLLBCL9CTNNB1HSD11B1 | |
| SCHEMBL23211936 | 0.90 | NOTUM (0.52) | NOTUMMGLLBCL9CTNNB1HSD11B1 | |
| SCHEMBL20757253 | 0.83 | RORC (0.48) | NOTUMMGLLBCL9CTNNB1HCRTR2 | |
| SCHEMBL29849889 | 0.83 | RORC (0.48) | NOTUMMGLLBCL9CTNNB1HCRTR2 | |
| SCHEMBL20743120 | 0.82 | USP30 (0.44) | NOTUMMGLLBCL9CTNNB1HSD11B1 | |
| SCHEMBL23859715 | 0.81 | MGLL (0.63) | NOTUMMGLLHSD11B1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021058445-A1 | NEW HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-20210094973-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094973-A1 | HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP1A1, CYP1B1 | NOTUM 3893/4885MGLL 3585/4885BCL9 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.